Ciphergen Biosystems said that its shareholders had elected Michael Callaghan, Kenneth Conway, and James Rathmann as Class I directors for three-year terms.
Thermo Fisher Scientific has named Michael Bell and Stephen Kaufman to its board. Bell is one of the managing directors of Monitor Clipper Partners, and Kaufman is a senior lecturer of business administration at the Harvard Business School.
Luminex named Douglas Bryant executive vice president and chief operating officer this week. He will oversee all elements of the company’s business, including worldwide sales, marketing, the company molecular diagnostics subsidiary, Luminex Molecular Diagnostics, the Luminex Bioscience Group, and the company’s manufacturing and worldwide service and support services.
Prior to joining Luminex, Bryant was at Abbott, most recently as vice president of Abbott Vascular in Asia and Japan.
Lumera this week named Michael Cicirelli, Ronald Dudek, and Todd Schwoerer to positions at Plexera Biosciences. Lumera spun out its biosciences business to form Plexera.
Cicirelli is director of application development; Dudek is director of business development; and Schwoerer is director of operations.
Shamrock Structures, a protein crystallography, structural biology, and synchrotron beamline services firm, this week appointed Richard Walter its CSO. He was most recently an associate research fellow at Pfizer. Before that, he was at Proctor & Gamble.
Crucell this week announced the appointment of Herbert Heyneker as senior vice president of R&D for the company’s new protein business unit. He was formerly chief technical officer at Eos Biotechnology. Oya Yavuz also has joined the company as director of investor relations. She was vice president of investor relations at Wolters Kluwer. And Kuno Sommer, chief business officer, will leave Crucell in September, the company said.